It has been approved for the treatment of multiple subgroups, including newly diagnosed CLL, R/R CLL, and elderly CLL patients, irrespective of high-risk gene lesions (TP53 mutation, IGHV mutation, and del(17p)) [122]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.